HDAC9 and cancer: One class of such inhibitors is histone deacetylase (HDAC) inhibitors, which have been under continued development for treating many diseases including cancers and neurological disorders since their excellent therapeutic efficacy was proven for treating cutaneous T cell lymphoma (Duvic et al., 2007; Falkenberg and Johnstone, 2014; Zagni et al., 2017).